Acurx Pharmaceuticals, Inc. Financing Cash Flow
Acurx Pharmaceuticals, Inc. (ACXP) reported Financing Cash Flow of $6.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.11M, a 0.67% increase year-over-year.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.11M, a 3.93% increase year-over-year.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.83M, a 1356.74% increase year-over-year.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.72M, a 8.30% increase year-over-year.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $10.64M, a 60.78% increase from fiscal 2024.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.62M, a 18.96% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.16M, a 120.92% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $3.70M, a 75.03% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.22M 10-Q · filed 2026-08-13 | $9.05M derived: sum of 3 quarters · filed 2026-08-13 | $10.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.11M 10-Q · filed 2026-05-11 | $5.94M derived: sum of 2 quarters · filed 2026-05-11 | $7.66M derived: sum of 3 quarters · filed 2026-05-11 | $10.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.56M derived: sum of 2 quarters · filed 2026-03-12 | $7.65M derived: sum of 3 quarters · filed 2026-08-13 | $10.64M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.81M derived: sum of 2 quarters · filed 2026-08-13 | $7.80M 10-Q · filed 2025-11-12 | $8.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.08M 10-Q · filed 2026-08-13 | $6.27M derived: sum of 3 quarters · filed 2026-08-13 | $7.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.99M 10-Q · filed 2026-05-11 | $3.18M derived: sum of 2 quarters · filed 2026-05-11 | $4.77M derived: sum of 3 quarters · filed 2026-05-11 | $5.09M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $194.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.79M derived: sum of 2 quarters · filed 2026-03-12 | $2.11M derived: sum of 3 quarters · filed 2026-03-12 | $6.62M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.91M derived: sum of 2 quarters · filed 2025-11-12 | $6.42M 10-Q · filed 2025-11-12 | $11.04M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $320.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.83M 10-Q · filed 2025-08-11 | $9.45M derived: sum of 3 quarters · filed 2025-08-11 | $9.45M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $4.51M 10-Q · filed 2025-05-12 | $9.13M derived: sum of 2 quarters · filed 2025-05-12 | $9.13M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.62M derived: sum of 2 quarters · filed 2025-03-17 | $8.16M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.54M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $3.54M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.70M 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $3.70M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $14.80M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $14.80M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $14.80M 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $728.54K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $2.92M derived: sum of 2 quarters · filed 2022-03-16 | $4.04M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $3.32M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $1.12M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |